Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Tumour Immunity induced in Mice with Cell-free Homogenates of Influenza Virus-infected Tumour Cells

Abstract

THE concept of reinforcing the immunological rejection reaction to a tumour by immunizing the host with tumour cells which have been modified by the introduction of a “helper determinant” onto their surfaces has been reviewed recently1. In general, tumour specific transplantation antigens (TSTA) on the surface membranes of tumour cells stimulate a relatively weak rejection reaction. If a strongly immunogenic determinant is coupled to the tumour cells, and the cells are then inoculated back into the host, a more intense immune response may be elicited which is also active against the TSTA alone. The helper determinant can be a hapten, a protein, a histocompatibility antigen (introduced into the tumour cell by hybridization with allogeneic cells), or a myxovirus which matures at the tumour cell surface. An early example of the use of a myxovirus as helper determinant is the work of Lindenmann and Klein2, who showed that A2G mice could be made immune to challenge with Ehrlich ascites tumour cells by vaccinating them with a cell-free homogenate of tumour cells which had been infected with influenza virus. Vaccination with a mechanical homogenate of uninfected tumour cells was without protective effect. Axler and Girardi3 prevented the expected appearance of tumours in hamsters due to inoculation of newborns with SV40 virus by vaccinating them during the latent period with homogenates of Newcastle disease virus-infected, SV40-transformed hamster tumour cells. Frozen-thawed lysates of non-NDV-infected SV40-transformed cells had no effect. We report here that BALB/c mice can be made immune to challenge with syngeneic, SV40-transformed fibrosarcoma cells by vaccinating them with cell-free homogenates of tumour cells which have been infected with influenza virus. No immunity is induced by vaccinating the mice with homogenates of influenza virus-infected normal cells, or with homogenates of tumour cells not previously infected with influenza virus.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Mitchison, N. A., Transplant. Proc., 2, 92 (1970).

    CAS  PubMed  Google Scholar 

  2. Lindenmann, J., and Klein, P. A., J. Exp. Med., 126, 93 (1967).

    Article  CAS  Google Scholar 

  3. Axler, D. A., and Girardi, A. J., Proc. Amer. Assoc. Cancer Res., No. 11 (1970).

  4. Aaronson, S. A., and Todaro, G. A., J. Cell. Physiol., 72, 144 (1968).

    Article  Google Scholar 

  5. Duc-Nguyen, H., Rose, H. M., and Morgan, C., Virology, 28, 404 (1966).

    Article  CAS  Google Scholar 

  6. Bretscher, P., and Cohn, Melvin, Science, 28, 1042 (1970).

    Article  ADS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

BOONE, C., BLACKMAN, K. & BRANDCHAFT, P. Tumour Immunity induced in Mice with Cell-free Homogenates of Influenza Virus-infected Tumour Cells. Nature 231, 265–266 (1971). https://doi.org/10.1038/231265a0

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1038/231265a0

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing